Can-Fite BioPharma Ltd. is evaluating its lead drug candidate for Hepatocellular carcinoma (HCC) and is conducting a Phase IIb study for MASH.
3 reports, 2 independent
Updated Jul 1
Gone quiet
- Reports
- 3
- Developments
- 2
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Can-Fite BioPharma Ltd. is evaluating its lead drug candidate for Hepatocellular carcinoma (HCC) and is conducting a Phase IIb study for MASH.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Can-Fite BioPharma Ltd. reported positive clinical trial updates for its drug Namodenoson.1 source
Company evaluating lead drug candidate for HCC and conducting Phase IIb study for MASH.1 source
Keep exploring
The entities involved
-
mash
fast genome and metagenome distance estimation using MinHash
Nothing else this week.